AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

The Chemours Company

$15.03 +$2.78 (+22.69%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$15.07
Day Range
$14.97$15.28
Year Range
$10.44$28.67
Market Cap
2.26B
AVG Volume
2.63M
Trailing/Forward PE
-7.51/7.67
PEG ratio
-0.08
Dividend Yield
2.33%
Next Earnings Date
2026-11-05
Primary Exchange
New York Stock ExchangeUS
Revenue (USD) · TTM
02B4B6B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q25.8B
26 Q15.82B
25 Q45.81B
25 Q35.87B
25 Q25.88B
25 Q15.82B
24 Q45.81B
24 Q35.83B
24 Q25.82B
24 Q15.9B
Net Income (USD) · TTM
-600M-400M-200M0200M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-304M
26 Q1-411M
25 Q4-386M
25 Q3-333M
25 Q2-420M
25 Q121M
24 Q479M
24 Q369M
24 Q2108M
24 Q1-328M
Operating Income (USD) · TTM
-500M-250M0250M500M750M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-304M
26 Q1-19M
25 Q4-5M
25 Q3329M
25 Q2347M
25 Q1405M
24 Q4440M
24 Q3472M
24 Q2460M
24 Q1525M
EBITDA (USD) · TTM
-250M0250M500M750M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-166M
26 Q1132M
25 Q4161M
25 Q3391M
25 Q2310M
25 Q1634M
24 Q4684M
24 Q3700M
24 Q2727M
24 Q1211M
Cash Flows (USD) · TTM
-1B-500M0500M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2125M
26 Q1154M
25 Q451M
25 Q3-12M
25 Q2-54M
25 Q1-797M
24 Q4-993M
24 Q3-675M
24 Q2-692M
24 Q110M
EPS (USD) · TTM
-3-2-10124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-1.99
26 Q1-2.72
25 Q4-2.56
25 Q3-2.22
25 Q2-2.8
25 Q10.21
24 Q40.58
24 Q30.46
24 Q20.77
24 Q1-2.22
Expenses (USD) · TTM
0500M1B1.5BR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q21.14B
26 Q11.09B
25 Q41.12B
25 Q3676M
25 Q2849M
25 Q1877M
24 Q4912M
24 Q3758M
24 Q2632M
24 Q1619M
Shares Outstanding (USD) · TTM
-50M-25M025M50M75MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CC Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-26M
26 Q1-19M
25 Q4-17M
25 Q3-20M
25 Q2-20M
25 Q1-19M
24 Q4-15M
24 Q3-16M
24 Q27M
24 Q147M
Dividends (USD)
00.10.20.3May 24Aug 24Nov 24Feb 25May 25Aug 25Nov 25Feb 26May 26Aug 26
CC Dividends (USD) by quarter
PeriodDividends (USD)
Aug 260.09
May 260.09
Feb 260.09
Nov 250.09
Aug 250.09
May 250.09
Feb 250.25
Nov 240.25
Aug 240.25
May 240.25
Employee Count
02K4K6K8K2016201720182019202020212022202320242025
CC Employee Count by quarter
PeriodEmployee Count
20255.7K
20246K
20236.2K
20226.6K
20216.4K
20206.5K
20197K
20187K
20177K
20167K
PE Ratio
0255075100125med 22.5Nov 22Feb 23Jun 23Sep 24Jan 25Apr 25Aug 25
CC PE Ratio by quarter
PeriodPE Ratio
Aug 2582.1
Jul 25101.16
Jul 2596.8
Jul 2598.66
Jul 2592.31
Jun 2583.67
Jun 2576.6
Jun 2578.39
Jun 2579.39
May 2572.32
May 2573.53
May 2579.74
May 2578.96
May 2523.71
Apr 2523.46
Apr 2521.54
Apr 2521.39
Apr 2520.14
Mar 2526.02
Mar 2526.74
Mar 2527.31
Mar 2526.78
Feb 2528.35
Feb 2531.79
Feb 2536.51
Feb 2539.62
Jan 2541.2
Jan 2542.67
Jan 2542.09
Jan 2538.27
Jan 2536.21
Dec 2436.9
Dec 2438.44
Dec 2441.31
Dec 2445.56
Nov 2447.17
Nov 2446.71
Nov 2440.98
Nov 2442.94
Nov 2424.65
Oct 2425.34
Oct 2427.18
Oct 2428.19
Oct 2427.07
Sep 2428.67
Sep 2425.87
Sep 2424.83
Sep 2424.17
Aug 2426.89
Aug 2426.7
Aug 2425.8
Aug 2425.07
Aug 2428.42
Jul 2311.71
Jul 2311.67
Jul 2311.28
Jun 2311.24
Jun 2310.2
Jun 2310.33
Jun 239.77
Jun 2310.25
May 238.69
May 239.04
May 238.62
May 238.99
Apr 238.86
Apr 237.33
Apr 237.74
Apr 237.4
Mar 237.77
Mar 237.48
Mar 237.44
Mar 238.1
Mar 239.53
Feb 238.76
Feb 239.11
Feb 238.92
Feb 236.14
Jan 236.01
Jan 235.77
Jan 235.75
Jan 235.54
Dec 225.24
Dec 225.27
Dec 225.27
Dec 225.05
Dec 225.37
Nov 225.61
Nov 225.66
Nov 225.76
Nov 225.18
Oct 224.91
Oct 225.23
Oct 224.67
Oct 224.67
Sep 224.37
Sep 224.47
Sep 225.58
Sep 226.33
Sep 225.89
Free Cash Flow Yield
-80%-60%-40%-20%0%20%med -2.31%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CC Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 265.49%
Sep 265.4%
Aug 265.29%
Aug 265.17%
Aug 265.21%
Aug 265.24%
Jul 266.17%
Jul 265.95%
Jul 265.85%
Jul 265.75%
Jul 265.39%
Jun 264.94%
Jun 264.7%
Jun 264.66%
Jun 265%
May 264.62%
May 264.79%
May 264.43%
May 264.45%
May 261.22%
Apr 261.27%
Apr 261.46%
Apr 261.49%
Apr 261.57%
Mar 261.57%
Mar 261.92%
Mar 261.93%
Mar 262.07%
Feb 261.86%
Feb 26-0.47%
Feb 26-0.39%
Feb 26-0.44%
Jan 26-0.53%
Jan 26-0.51%
Jan 26-0.51%
Jan 26-0.56%
Jan 26-0.65%
Dec 25-0.66%
Dec 25-0.68%
Dec 25-0.62%
Dec 25-0.63%
Nov 25-0.62%
Nov 25-0.72%
Nov 25-0.67%
Nov 25-0.64%
Oct 25-2.68%
Oct 25-2.56%
Oct 25-2.79%
Oct 25-2.86%
Oct 25-2.23%
Sep 25-2.3%
Sep 25-2.11%
Sep 25-2.15%
Sep 25-2.3%
Aug 25-2.33%
Aug 25-2.34%
Aug 25-2.46%
Aug 25-2.95%
Aug 25-46.23%
Jul 25-37.52%
Jul 25-39.21%
Jul 25-38.47%
Jul 25-41.12%
Jun 25-45.36%
Jun 25-49.55%
Jun 25-48.42%
Jun 25-47.81%
May 25-52.48%
May 25-51.61%
May 25-47.59%
May 25-48.07%
May 25-53.02%
Apr 25-53.58%
Apr 25-58.34%
Apr 25-58.76%
Apr 25-62.41%
Mar 25-48.31%
Mar 25-47%
Mar 25-46.03%
Mar 25-46.94%
Feb 25-44.33%
Feb 25-39.54%
Feb 25-26.79%
Feb 25-24.69%
Jan 25-23.74%
Jan 25-22.92%
Jan 25-23.24%
Jan 25-25.56%
Jan 25-27.02%
Dec 24-26.51%
Dec 24-25.45%
Dec 24-23.68%
Dec 24-21.47%
Nov 24-20.74%
Nov 24-20.94%
Nov 24-23.87%
Nov 24-22.78%
Nov 24-25.99%
Oct 24-25.28%
Oct 24-23.57%
Price to Sales
0.20.40.60.8med 0.41Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CC Price to Sales by quarter
PeriodPrice to Sales
Sep 260.39
Sep 260.4
Aug 260.41
Aug 260.42
Aug 260.41
Aug 260.41
Jul 260.43
Jul 260.44
Jul 260.45
Jul 260.46
Jul 260.49
Jun 260.54
Jun 260.56
Jun 260.57
Jun 260.53
May 260.57
May 260.55
May 260.6
May 260.6
May 260.72
Apr 260.69
Apr 260.6
Apr 260.59
Apr 260.56
Mar 260.56
Mar 260.46
Mar 260.45
Mar 260.42
Feb 260.47
Feb 260.44
Feb 260.53
Feb 260.47
Jan 260.38
Jan 260.4
Jan 260.4
Jan 260.37
Jan 260.31
Dec 250.31
Dec 250.3
Dec 250.33
Dec 250.32
Nov 250.33
Nov 250.28
Nov 250.3
Nov 250.32
Oct 250.34
Oct 250.36
Oct 250.33
Oct 250.32
Oct 250.41
Sep 250.4
Sep 250.43
Sep 250.43
Sep 250.4
Aug 250.39
Aug 250.39
Aug 250.37
Aug 250.31
Aug 250.3
Jul 250.37
Jul 250.35
Jul 250.36
Jul 250.33
Jun 250.3
Jun 250.28
Jun 250.28
Jun 250.29
May 250.26
May 250.27
May 250.29
May 250.29
May 250.32
Apr 250.32
Apr 250.29
Apr 250.29
Apr 250.27
Mar 250.35
Mar 250.36
Mar 250.37
Mar 250.36
Feb 250.39
Feb 250.43
Feb 250.43
Feb 250.47
Jan 250.49
Jan 250.51
Jan 250.5
Jan 250.45
Jan 250.43
Dec 240.44
Dec 240.46
Dec 240.49
Dec 240.54
Nov 240.56
Nov 240.55
Nov 240.49
Nov 240.51
Nov 240.46
Oct 240.47
Oct 240.5
EV/EBITDA
0204060med 14.28Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26Jul 26
CC EV/EBITDA by quarter
PeriodEV/EBITDA
Jul 2647.92
Jul 2648.61
Jul 2648.96
Jul 2649.29
Jul 2650.65
Jun 2652.62
Jun 2653.8
Jun 2654.06
Jun 2652.35
May 2654.24
May 2653.34
May 2655.35
May 2655.24
May 2650.21
Apr 2649.17
Apr 2645.96
Apr 2645.52
Apr 2644.44
Mar 2644.49
Mar 2640.85
Mar 2640.72
Mar 2639.64
Feb 2641.35
Feb 2616.27
Feb 2617.61
Feb 2616.76
Jan 2615.48
Jan 2615.78
Jan 2615.72
Jan 2615.22
Jan 2614.43
Dec 2514.37
Dec 2514.27
Dec 2514.7
Dec 2514.6
Nov 2514.64
Nov 2513.97
Nov 2514.29
Nov 2514.53
Oct 2519.09
Oct 2519.41
Oct 2518.85
Oct 2518.68
Oct 2520.41
Sep 2520.19
Sep 2520.84
Sep 2520.71
Sep 2520.19
Aug 2520.06
Aug 2520.05
Aug 2519.68
Aug 2518.5
Aug 258.9
Jul 259.53
Jul 259.38
Jul 259.45
Jul 259.24
Jun 258.95
Jun 258.72
Jun 258.77
Jun 258.81
May 258.57
May 258.61
May 258.82
May 258.79
May 258.06
Apr 258.03
Apr 257.81
Apr 257.8
Apr 257.65
Mar 258.33
Mar 258.41
Mar 258.48
Mar 258.42
Feb 258.6
Feb 259
Feb 258.88
Feb 259.18
Jan 259.34
Jan 259.48
Jan 259.43
Jan 259.05
Jan 258.85
Dec 248.91
Dec 249.07
Dec 249.35
Dec 249.77
Nov 249.93
Nov 249.88
Nov 249.32
Nov 249.51
Nov 248.66
Oct 248.76
Oct 249.03
Oct 249.18
Oct 249.02
Sep 249.25
Sep 248.84
Sep 248.68
Sep 248.59
Price/Operating Cashflow
510152025med 9.37Dec 23Mar 24Jul 24Oct 25Feb 26May 26Sep 26
CC Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 266.45
Sep 266.56
Aug 266.7
Aug 266.85
Aug 266.8
Aug 266.75
Jul 267.52
Jul 267.8
Jul 267.93
Jul 268.07
Jul 268.61
Jun 269.39
Jun 269.86
Jun 269.96
Jun 269.28
May 2610.04
May 269.68
May 2610.47
May 2610.43
May 2615.79
Apr 2615.15
Apr 2613.2
Apr 2612.93
Apr 2612.27
Mar 2612.3
Mar 2610.08
Mar 2610.01
Mar 269.35
Feb 2610.39
Feb 269.66
Feb 2611.63
Feb 2610.39
Jan 268.5
Jan 268.93
Jan 268.85
Jan 268.11
Jan 266.94
Dec 256.85
Dec 256.7
Dec 257.34
Dec 257.2
Nov 257.25
Nov 256.26
Nov 256.74
Nov 257.09
Oct 257.8
Oct 258.18
Oct 257.51
Oct 257.31
Oct 259.39
Sep 259.12
Sep 259.91
Sep 259.75
Sep 259.12
Aug 258.97
Aug 258.95
Aug 258.51
Aug 257.1
Jul 249.27
Jul 248.95
Jul 249.34
Jul 248.43
Jun 248.6
Jun 248.73
Jun 249.29
Jun 249.21
May 249.46
May 2410.13
May 2411.01
May 2411.02
May 2410.13
Apr 247.29
Apr 246.91
Apr 247.06
Apr 247.21
Mar 247.01
Mar 2417.62
Mar 2417.16
Mar 2416.34
Mar 2413.14
Feb 2418.64
Feb 2417.78
Feb 2419.03
Feb 2419.38
Jan 2419.79
Jan 2418.48
Jan 2419.09
Jan 2419.78
Dec 2319.95
Dec 2320.11
Dec 2319.25
Dec 2318.28
Dec 2318.77
Nov 2316.68
Nov 2317.25
Nov 2315.44
Nov 2316.24
Oct 2314.91
Oct 239.22
Oct 239.47
Price to Book
05101520med 5.94Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26Jul 26
CC Price to Book by quarter
PeriodPrice to Book
Jul 2611.56
Jul 2611.99
Jul 2612.2
Jul 2612.4
Jul 2613.23
Jun 2614.44
Jun 2615.15
Jun 2615.31
Jun 2614.27
May 2615.42
May 2614.88
May 2616.1
May 2616.04
May 2616.61
Apr 2615.94
Apr 2613.89
Apr 2613.6
Apr 2612.91
Mar 2612.94
Mar 2610.6
Mar 2610.52
Mar 269.83
Feb 2610.93
Feb 268.53
Feb 2610.28
Feb 269.17
Jan 267.51
Jan 267.89
Jan 267.82
Jan 267.16
Jan 266.13
Dec 256.05
Dec 255.92
Dec 256.49
Dec 256.36
Nov 256.41
Nov 255.53
Nov 255.95
Nov 256.26
Oct 258.42
Oct 258.83
Oct 258.11
Oct 257.89
Oct 2510.14
Sep 259.84
Sep 2510.69
Sep 2510.53
Sep 259.84
Aug 259.68
Aug 259.66
Aug 259.19
Aug 257.66
Aug 252.97
Jul 253.66
Jul 253.5
Jul 253.57
Jul 253.34
Jun 253.03
Jun 252.77
Jun 252.84
Jun 252.87
May 252.62
May 252.66
May 252.89
May 252.86
May 253.1
Apr 253.06
Apr 252.81
Apr 252.79
Apr 252.63
Mar 253.4
Mar 253.49
Mar 253.57
Mar 253.5
Feb 253.7
Feb 254.15
Feb 253.82
Feb 254.15
Jan 254.31
Jan 254.47
Jan 254.41
Jan 254.01
Jan 253.79
Dec 243.86
Dec 244.03
Dec 244.33
Dec 244.77
Nov 244.94
Nov 244.89
Nov 244.29
Nov 244.5
Nov 243.67
Oct 243.78
Oct 244.05
Oct 244.2
Oct 244.03
Sep 244.27
Sep 243.85
Sep 243.7
Sep 243.6
The Chemours Company
CC
Stockpicker

Video analysis: CC

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CC

Baron & Budd Secures $380 Million Settlement With DuPont, Chemours, and Corteva Over North Carolina PFAS Contamination

businesswire.com · 10 Sep 2026

Baron & Budd Secures $380 Million Settlement With DuPont, Chemours, and Corteva Over North Carolina PFAS Contamination

DALLAS--(BUSINESS WIRE)--Baron & Budd has secured a $380 million settlement with DuPont, The Chemours Company, and Corteva on behalf of 11 North Carolina public entities to resolve claims arising from PFAS contamination. The entities - Bladen County, Brunswick County, Columbus County, Cumberland County, New Hanover County, Robeson County, Sampson County, Town of Wrightsville Beach, City of Lumberton, Village of Bald Head Island, and Lower Cape Fear Water and Sewer Authority – sought compens.

Chemours, DuPont, Corteva settle North Carolina 'forever chemicals' claims for $455 million

reuters.com · 10 Sep 2026

Chemours, DuPont, Corteva settle North Carolina 'forever chemicals' claims for $455 million

Chemours , DuPont and Corteva on Thursday reached a $455 million settlement with North Carolina and 11 ​local entities over PFAS contamination claims tied ‌to Chemours' Fayetteville Works plant and other historical discharges.

DuPont, Chemours and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina

prnewswire.com · 10 Sep 2026

DuPont, Chemours and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina

Resolves litigations brought by the State of North Carolina and 11 local entities relating to PFAS and other historical discharges from Fayetteville Works, as well as the State's claims of PFAS contamination unrelated to that site, including from the use of aqueous film forming foam ("AFFF"). Settlement payments over 15 years, with a net present value of approximately $355 million to be shared by DuPont, Chemours and Corteva.

Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina

prnewswire.com · 10 Sep 2026

Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina

Resolves litigations brought by the State of North Carolina and 11 local entities relating to PFAS and other historical discharges from Fayetteville Works, as well as the State's claims of PFAS contamination unrelated to that site, including from the use of aqueous film forming foam ("AFFF"). Overall settlement payments total $455 million over 15 years; Chemours' 50% share of payments of approximately $180 million on a net present value basis, which are covered by existing accruals.

Lululemon (LULU) Faces Challenges After Disappointing Q2 Results

gurufocus.com · 4 Sep 2026

Lululemon (LULU) Faces Challenges After Disappointing Q2 Results

Lululemon athletica (LULU) is experiencing significant pressure following its disappointing Q2 results, with shares dropping below $100 for the first time in se

Chemours (CC) Up 7.5% Since Last Earnings Report: Can It Continue?

zacks.com · 3 Sep 2026

Chemours (CC) Up 7.5% Since Last Earnings Report: Can It Continue?

Chemours (CC) reported earnings 30 days ago. What's next for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company ("Chemours" or the "Company") (NYSE: CC).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.